CFO Raphi Levy spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The Israel-based company is looking to treat solid tumor cancer with its interstitial radioactive seed technology that continually releases short-lived alpha-emitting atoms into the tumor. Recently, the company revealed results from its first clinical trial in patients with squamous cell carcinoma.